Thymosin Alpha-1: What the Published Research Reports

Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide described in the literature as a naturally occurring thymic peptide that has been studied for its effects on immune function [1][4]. Early immunochemical work in humans established a radioimmunoassay capable of detecting the peptide in serum and plasma, and reported that circulating concentrations were highest in utero, declined sharply after birth, and remained relatively constant over the first 15 years of life [2]. A subsequent human serum survey using radioimmunoassay reported normal thymosin alpha-1 levels of approximately 670 pg/mL in male and 652 pg/mL in female donors, and compared these with cord blood and with serum from homosexual men and AIDS patients, finding elevated levels of thymosin alpha-1 and/or thymosin beta-4 in a proportion of samples without correlation between the two peptides [3]. Mechanistic work has been conducted largely in cells. In murine thymocytes studied in vitro, Tα1 was reported to antagonise dexamethasone- and anti-CD3-induced DNA fragmentation, with the effect localised to CD4+CD8+ immature thymocytes; the authors reported delayed free-radical production and glutathione consumption, and stimulation of cAMP production and protein kinase C activation as candidate second-messenger pathways [4]. A separate in vitro study using a clonogenic K562 assay examined lymphokine-activated killer (LAK) cell activity from patients with primary immunodeficiencies and reported that suppressed LAK activity was improved in some individual samples by Tα1 exposure, while moderately reduced activity in common variable immunodeficiency samples was unaffected [5]. Work addressing safety-relevant questions in vitro reported no effect of exogenous Tα1 on tumour cell growth, and that NIH-3T3 cells transfected with prothymosin alpha cDNA expressed elevated Tα1 but showed neither enhanced proliferation nor loss of contact inhibition or anchorage-independent growth [6]. Not all preclinical hypotheses have replicated. Two independent cell-based investigations in cystic fibrosis airway epithelial models — including primary bronchial epithelial cells from CF patients — reported that Tα1 was devoid of activity on F508del-CFTR maturation and gating and on the calcium-activated chloride channel [7][8]. The authors of the later report noted that, across six independent laboratories, correction of F508del-CFTR by Tα1 was not demonstrated, while stating that immunomodulatory effects of the peptide were not excluded by those experiments [8]. In human clinical literature, Tα1 has been reviewed in chronic hepatitis B, where a review of English- and Chinese-language trial databases summarised studies of monotherapy and of combination with nucleos(t)ide analogues or interferon and their reported effects on HBV DNA suppression and HBeAg seroconversion [9]. A prospective multicentre randomised open-label study in 690 patients with HBV-related compensated cirrhosis compared Tα1 plus entecavir with entecavir alone and reported similar cumulative incidence of liver decompensation, hepatocellular carcinoma or death between groups over a median 38.2 months of follow-up, with both regimens described as well tolerated [10]. Sepsis has been a recurring clinical research setting. A narrative review summarised clinical studies of Tα1 alone and in combination, noting reported reductions in mortality, changes in monocyte HLA-DR expression and secondary infection incidence, while emphasising the heterogeneity of sepsis as a syndrome [11]. A later systematic review and meta-analysis of 11 randomised controlled trials (967 Tα1 and 960 control patients) reported a reduction in 28-day mortality overall (OR 0.73, 95% CI 0.59–0.90), but no statistically significant effect in the high-quality (OR 0.82, 95% CI 0.65–1.03) or multicentre (OR 0.86, 95% CI 0.68–1.08) subgroups, with trial sequential analysis indicating the pooled sample size was inadequate [12]. In severe acute pancreatitis, a systematic review and meta-analysis of five randomised controlled trials comprising 706 patients reported increases in CD4+ percentages and in the CD4+/CD8+ ratio, a reduction in the overall incidence of extrapancreatic infection (RR 0.56, 95% CI 0.40–0.78), a reduction in APACHE II score, and no statistically significant change in length of hospital stay [13]. A separate multicentre, randomised, double-blind, placebo-controlled trial protocol described a planned 520-patient study of Tα1 in acute necrotising pancreatitis with infected pancreatic necrosis during index admission as the primary endpoint [14]. COVID-19 generated conflicting human data. A multicentre cohort study of 2,282 patients in Hubei province reported that, after adjustment for confounders, Tα1 use was associated with a higher non-recovery rate than non-use (OR 1.5, 95% CI 1.1–2.1), with larger associations in more severely ill subgroups [15]. A small prospective open-label randomised pilot trial in 49 hospitalised patients with hypoxaemia and lymphocytopenia reported no significant difference in clinical recovery incidence, but reported a greater relative increase in CD4+ T-cell count by day 5 among treated patients on baseline low-flow oxygen [16]. A comprehensive literature review discussed the peptide's reported use in immunocompromised states, as a vaccine-response enhancer, and its proposed investigation in COVID-19 [17]. Oncology and ageing have also been reviewed rather than resolved. An early review summarised experimental and human cancer studies of Tα1 combined with low-dose interferon or interleukin-2 and with chemotherapy [18]. A recent review described Tα1's reported regulation of T-cell maturation, Th1 polarisation, natural killer cell activity, dendritic cells, tumour-associated macrophages and myeloid-derived suppressor cells across preclinical and clinical studies, while characterising the available clinical evidence in non-small cell lung cancer, hepatocellular carcinoma and metastatic melanoma as limited and heterogeneous [19]. A review of HIV-1 literature summarised in vitro and in vivo studies of Tα1 in the context of incomplete immune reconstitution during antiretroviral therapy [20]. A 2025 review of ageing and Tα1 discussed thymic involution and summarised preclinical and clinical reports on T-cell differentiation, thymic output, dendritic cell and macrophage modulation, and vaccine response in elderly populations, concluding that further research is needed to validate long-term efficacy and safety [1].